Milestone Pharmaceuticals Inc

詳細情報 Milestone Pharmaceuticals Inc 企業名

Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia (PSVT) with a subsequent indication to treat atrial fibrillation with rapid ventricular rate (AFib-RVR) and other cardiovascular indications.

企業情報

企業コードMIST

会社名Milestone Pharmaceuticals Inc

上場日May 09, 2019

最高経営責任者「CEO」Mr. Joseph Oliveto

従業員数33

証券種類Ordinary Share

決算期末May 09

本社所在地420-1111 boul. Dr.-Frederik-Philips

都市MONTREAL

証券取引所NASDAQ Global Select Consolidated

国Canada

郵便番号H4M 2X6

電話番号15143360444

ウェブサイトhttps://www.milestonepharma.com

企業コードMIST

上場日May 09, 2019

最高経営責任者「CEO」Mr. Joseph Oliveto

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. David Bharucha

Chief Medical Officer

78.45K

+212.30%

Mr. Amit Hasija

Chief Financial Officer, Executive Vice President - Corporate Development

69.20K

+260.35%

Dr. Robert James Wills, Ph.D.

Non-Executive Independent Chairman of the Board

65.00K

+333.33%

Mr. Michael John Tomsicek

Independent Director

15.00K

--

Mr. Stuart Duty

Independent Director

--

Mr. Joeseph C. Papa

Independent Director

--

Mr. Andrew Saik

Independent Director

--

Ms. Lisa M. Giles

Independent Director

--

Mr. Joseph Oliveto

President, Chief Executive Officer, Director

--

Mr. Lorenz Muller

Chief Commercial Officer

--

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. David Bharucha

Chief Medical Officer

78.45K

+212.30%

Mr. Amit Hasija

Chief Financial Officer, Executive Vice President - Corporate Development

69.20K

+260.35%

Dr. Robert James Wills, Ph.D.

Non-Executive Independent Chairman of the Board

65.00K

+333.33%

Mr. Michael John Tomsicek

Independent Director

15.00K

--

Mr. Stuart Duty

Independent Director

--

Mr. Joeseph C. Papa

Independent Director

--

収益内訳

データなし

データなし

事業別

地域別

データなし

株主

更新時刻: Sat, Sep 13

株主統計

種類

株主統計

比率

Trails Edge Capital Partners LP

6.27%

Oliveto (Joseph Gerard)

2.95%

RTW Investments L.P.

2.95%

Propel Bio Management, LLC

2.11%

Alta Fundamental Advisers LLC

1.65%

他の

84.07%

株主統計

比率

Trails Edge Capital Partners LP

6.27%

Oliveto (Joseph Gerard)

2.95%

RTW Investments L.P.

2.95%

Propel Bio Management, LLC

2.11%

Alta Fundamental Advisers LLC

1.65%

他の

84.07%

種類

株主統計

比率

Investment Advisor

10.40%

Individual Investor

3.61%

Investment Advisor/Hedge Fund

3.03%

Hedge Fund

2.31%

Venture Capital

2.30%

Research Firm

2.16%

Bank and Trust

0.02%

他の

76.18%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

99

14.54M

18.86%

-15.65M

2025Q1

102

12.26M

22.94%

-17.24M

2024Q4

99

25.17M

47.19%

-9.38M

2024Q3

113

29.31M

55.02%

-13.44M

2024Q2

115

30.81M

57.87%

-11.80M

2024Q1

116

31.96M

60.43%

+3.19M

2023Q4

112

18.49M

55.02%

-13.59M

2023Q3

109

20.24M

60.32%

-12.06M

2023Q2

108

21.35M

63.87%

-11.78M

2023Q1

110

22.19M

66.58%

-11.98M

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

Oliveto (Joseph Gerard)

2.44M

4.57%

+2.16M

+756.94%

Apr 15, 2025

RTW Investments L.P.

2.51M

4.69%

--

Mar 31, 2025

Propel Bio Management, LLC

1.45M

2.71%

+1.25M

+625.78%

Mar 31, 2025

Alta Fundamental Advisers LLC

1.43M

2.67%

-1.23M

-46.31%

Mar 31, 2025

BML Capital Management LLC

1.14M

2.13%

--

Mar 31, 2025

Simplify Asset Management Inc

850.00K

1.59%

+850.00K

--

Mar 31, 2025

Morgan Stanley & Co. LLC

965.92K

1.81%

-320.62K

-24.92%

Mar 31, 2025

TD Securities, Inc.

750.00K

1.4%

--

Mar 31, 2025

Lion Point Capital, L.P.

548.81K

1.03%

-477.00K

-46.50%

Mar 31, 2025

詳細を見る

1.920USD

Milestone Pharmaceuticals Inc

1.920

概要

企業名

金融

分析